Stock KDST KADIMASTEM LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Kadimastem Ltd

Equities

KDST

IL0011284614

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 07:24:09 2024-04-25 EDT 		5-day change 1st Jan Change
494.7 ILa +1.33% Intraday chart for Kadimastem Ltd +5.28% -16.58%
03-28 Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-28 IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company
MT
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC
AQ
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company
AQ
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.
CI
Kadimastem Plans Listing on Nasdaq Through Merger
CI
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
AQ
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
AQ
A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology
AQ
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
AQ
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products
CI
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
AQ
Kadimastem Ltd announced that it expects to receive ILS 6.783 million in funding from Alpha Capital Anstalt and another investor
CI
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
AQ
Kadimastem : Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS
PR
Kadimastem : Announces Executive Management Changes
PR
Kadimastem : AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial
AQ
Kadimastem : Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS
PR
Kadimastem : Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KDST Stock
  4. News Kadimastem Ltd